Quick Answer
IONIS PHARMACEUTICALS INC reported Net Income Loss of -$381.39 million for the year ending 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +16.0% in Net Income Loss from 2024 to 2025.
- This data is from IONIS PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2010: -$9.66 million | Q2 2010: -$25.15 million | Q3 2010: -$12.45 million | Q1 2011: -$19.99 million | Q2 2011: -$17.89 million | Q1 2014: -$31.28 million | Q2 2014: -$12.08 million | Q3 2014: -$26.68 million | Q4 2014: $31.05 million | Q1 2015: -$16.72 million | Q2 2015: $35.65 million | Q3 2015: -$35.78 million | Q4 2015: -$71.43 million | Q1 2016: -$62.92 million | Q2 2016: -$56.86 million | Q3 2016: $7.35 million | Q4 2016: $25.87 million | Q1 2017: $8.96 million | Q2 2017: -$3.09 million | Q3 2017: -$2.61 million | Q4 2017: -$2.92 million | Q1 2018: -$1.42 million | Q2 2018: -$40.36 million | Q3 2018: -$4.56 million | Q4 2018: $320.08 million | Q1 2019: $84.44 million | Q2 2019: -$876.0 thousand | Q3 2019: $26.16 million | Q4 2019: $184.42 million | Q1 2020: -$39.63 million | Q2 2020: -$25.64 million | Q3 2020: -$24.47 million | Q4 2020: -$354.53 million | Q1 2021: -$89.87 million | Q2 2021: -$80.88 million | Q3 2021: -$82.47 million | Q4 2021: $224.61 million | Q1 2022: -$65.17 million | Q2 2022: -$105.14 million | Q3 2022: -$46.99 million | Q4 2022: -$52.43 million | Q1 2023: -$124.32 million | Q2 2023: -$85.29 million | Q3 2023: -$147.41 million | Q4 2023: -$9.26 million | Q1 2024: -$142.80 million | Q2 2024: -$66.27 million | Q3 2024: -$140.48 million | Q4 2024: -$104.35 million | Q1 2025: -$146.94 million | Q2 2025: $123.55 million | Q3 2025: -$128.61 million | Q4 2025: -$229.39 million.
- Over the full 16 years of available data (2008 to 2025), IONIS PHARMACEUTICALS INC's Net Income Loss has declined by 1,998.8%.
- Historical annual values: Fiscal year 2025: -$381.39 million | Fiscal year 2024: -$453.90 million | Fiscal year 2023: -$366.29 million | Fiscal year 2022: -$269.72 million | Fiscal year 2021: -$28.60 million | Fiscal year 2020: -$444.26 million | Fiscal year 2019: $278.14 million | Fiscal year 2018: $273.74 million | Fiscal year 2017: $346.0 thousand | Fiscal year 2016: -$60.40 million | Fiscal year 2015: -$88.28 million | Fiscal year 2014: -$38.98 million | Fiscal year 2013: -$60.64 million | Fiscal year 2010: -$61.25 million | Fiscal year 2009: $155.07 million | Fiscal year 2008: -$18.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: